![EuroAPI Header](https://www.pharmacompass.com/image/flap/euroapi-w34-desktop-headergif-72716.gif)
![EuroAPI Header](https://www.pharmacompass.com/image/flap/euroapi-w34-mob-headergif-95876.gif)
Upload your Marketing & Sales content on your company Virtual Booth, click HERE.
Details:
The Phase II SBIR funding will be used to develop a formulation of VPX638 (sevoflurane) and to further characterize the anti-inflammatory and analgesic profile in animal disease models.
Lead Product(s): Sevoflurane
Therapeutic Area: Trauma (Emergency, Injury, Surgery) Product Name: VPX638
Highest Development Status: Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: National Institute of Arthritis and Musculoskeletal and Skin Diseases
Deal Size: $1.5 million Upfront Cash: Undisclosed
Deal Type: Funding November 11, 2020